As a result, there are more than 1,000 immunotherapy trials underway, and the number keeps growing. Its hard to imagine we can support more than 1,000 studies, said Dr. Daniel Chen, a vice president at Genentech, a biotechnology company.
In a commentary in the journal Nature, he and Ira Mellman, also a vice president at the company, wrote that the proliferating trials have outstripped our progress in understanding the basic underlying science.
I think there is a lot of exuberant rush to market, said Dr. Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. And we are squandering our most precious resource patients.
Take melanoma: There are more than 85,000 cases a year in the United States, according to Dr. Norman Sharpless, director of the Lineberger Comprehensive Cancer Center at the University of North Carolina, who was recently named director of the National Cancer Institute.
Most melanomas are cured by surgery, leaving about 10,000 patients who have had relapses and could be candidates for an experimental treatment. But nearly all will be treated by doctors outside of academic medical centers, who are not part of the clinical trials network and so do not offer patients experimental treatments.
Companies therefore must compete for the few patients with relapsed melanoma who are at centers offering clinical trials. Many end up struggling to find enough subjects to determine whether a treatment actually works and if so, for whom.
And these drugs often are not so different from one another.
Immunotherapy drugs that attack a protein known as PD-1 are approved for treatment of lung cancer, renal cell cancer, bladder cancer and Hodgkins disease, noted Dr. Richard Pazdur, director of the F.D.A.s Oncology Center of Excellence.
Yet many pharmaceutical companies want their own anti-PD-1. Companies are hoping to combine immunotherapy drugs with other cancer drugs for added effect, and many do not want to have to rely on a competitors anti-PD-1 drug along with their own secondary drugs.
So in new trials, additional anti-PD-1 drugs are being tested all over again against the same cancers a me-too business strategy taken to multibillion-dollar extremes.
How many PD-1 antibodies does Planet Earth need? wondered Dr. Roy Baynes, a senior vice president at Merck, which received approval for its first such drug in 2014.
Immunotherapy trials have proliferated so quickly that major medical centers are declining to furnish patients to them. The Yale Cancer Center participates in fewer than 10 percent of the immunotherapy trials it is asked to join.
The problem is that many of the trials are uninteresting from a scientific view, said Dr. Roy Herbst, the centers chief of medical oncology. The companies sponsoring these trials are not addressing new research questions, he said; they are trying to get proprietary drugs approved.
If the struggle to find patients for immunotherapy trials is challenging, finding patients for another new type of cancer treatment can be next to impossible.
These are drugs that attack mutations that tumors need to grow and thrive so-called targeted therapies. The idea is that tumors can be reliant on certain gene mutations. Block those mutations and the tumors will die.
The problem is that the mutations can be extraordinarily rare. Most patients who have cancers with the mutation in question have no idea; to find them, large groups of cancer patients must have their tumors genetically tested.
Thats expensive: Genetic sequencing costs about $5,000, and insurers rarely pay. Most cancer patients treated outside of academic centers do not have their tumors sequenced.
So what to do if youre a company with a drug that seems to be dramatically effective, but only in a few patients?
You may be forced to undertake a worldwide search for subjects that can last for years.
To test a two-drug combination against lung cancer, GlaxoSmithKline searched the United States, Japan, South Korea and Europe for 13 months just to find 59 patients whose tumors shared a rare mutation.
It took Pfizer three years to locate 50 lung cancer patients who carried a rare aberration called ROS1, found in just 1 percent of patients.
Clinical trials with patient searches like these are not for the faint of heart, said Dr. Mace Rothenberg, a senior vice president at Pfizer.
It helps that the F.D.A. has not insisted on large trials with control groups in instances of targeted therapies with few who qualify.
Instead the agency is looking for drugs with effects so powerful there is no question that they work studies in which patients went into remission, for example, when all evidence suggested they would die.
We used to have trials not long ago that had 700 patients per arm, Dr. Sharpless said, referring to the treatment groups in a study. Thats almost undoable now.
Today, trials can be eight patients.
To test a drug that attacks a tumor with a mutation found in just 1 percent of cancer patients, researchers at Memorial Sloan Kettering fanned out to the nonacademic medical centers where the majority of patients are treated, offering to pay for most of the cost of genetic testing, seeking patients at practices in the Lehigh Valley of Pennsylvania; Hartford, Conn.; and Miami.
That is how Bruce Fenstermacher, 67, a retired long-distance truck driver who lives in Allentown, Pa., discovered he had the rare mutation that the drugs manufacturer, Loxo Oncology, had been looking for.
He had been receiving immunotherapy for his melanoma, but it had stopped working and his cancer was spreading again. Discovering that mutation was like hitting the jackpot for Mr. Fenstermacher, said Dr. Suresh Nair, an oncologist with Lehigh Valley Health Network.
The experimental drug seems to be working for Mr. Fenstermacher. But since so few patients have tumors that might respond, oncologists wonder how they will find them.
Is it worth it? Is it even possible?
If, God forbid, I had a family member with cancer, I would insist on this type of testing, said Dr. David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center. But I dont know what the rate has to be for society to say, We cant afford to miss these people.
And trials involving limited numbers of patients can be perilous. The smaller the study and the shorter its duration, the more likely that what looks like an effect in a trial might simply be a result of chance, Dr. Bach of Memorial Sloan Kettering said.
That leaves some of us evidence geeks wondering if it works, he said.
Some of the new cancer drugs have had such impressive results that their effectiveness was not in doubt, said Dr. Vinay Prasad, an oncologist at Oregon Health and Sciences University.
But, there also were drugs approved without control groups that did not provide such stunning benefits, and others that markedly slowed the growth of tumors but did not extend life.
In tiny studies, serious side effects can be missed, said Dr. Scott Ramsey, an oncologist at the Fred Hutchinson Cancer Research Center.
He worries about the expense of the new drugs, including out-of-pocket costs to patients. They may want the new cancer drugs reaching the market, he said, but you wonder if you are doing them any favors.
Read the original here:
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients - New York Times
- Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation - Madrona Venture Group - January 6th, 2025
- Personalized medicine: The pros, cons and concerns - New Atlas - November 16th, 2024
- Precision Medicine, AI, and the Future of Personalized Health Care - November 16th, 2024
- Why precision medicine results in more effective health care, treatment plans - The Business Journals - November 16th, 2024
- Comprehensive Genomic Profiling at Diagnosis Extends Survival in Patients with Advanced Cancer - Inside Precision Medicine - November 16th, 2024
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022
- PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV - June 8th, 2022
- BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India - June 8th, 2022
- Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance - June 8th, 2022
- Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal - June 8th, 2022
- 57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News - June 8th, 2022
- Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com - June 8th, 2022
- Inspiration for the laboratory of tomorrow - Chemie.de - June 8th, 2022
- Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia... - May 8th, 2022
- The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance - May 8th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 8th, 2022
- Link between EBV and MS may give clues to the cause of long COVID - The Arizona Republic - May 8th, 2022
- Improving Cell Cultures with Thermoresponsive Coatings - Genetic Engineering & Biotechnology News - May 8th, 2022
- Reevaluating, Reimagining, And Reinventing Healthcare: Innovation In A Post-Pandemic World - Forbes - May 8th, 2022
- Study of Cancer Genetics to Help with Targeted Treatment - VOA Learning English - May 8th, 2022
- Increased demand for Molecular diagnostics after the COVID-19 outbreak - The Financial Express - May 8th, 2022
- CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News - January 30th, 2022
- SeqOne Genomics Closes 20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform - Business Wire - January 30th, 2022
- Study: In IBS patients, cognitive behavioral therapy modulates the brain-gut microbiome and helps relieve symptoms - UB News Center - January 30th, 2022
- (New Report) Digital Genome Market In 2022 : The Increasing use in Diagnostics, Agriculture & Animal Research, Personalized Medicine, Drug... - January 30th, 2022
- Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health - January 30th, 2022
- Plants, Bioprinting and Orbital Plumbing Fill Crew's Thursday Schedule - NASA - January 30th, 2022